DeutschNewstral
Article
jdsupra.com on 2024-05-13 20:53
Summary and Key Considerations of Recent HHS-OIG Advisory Opinion on Pharmaceutical Patient Assistance Program for Rare Disorders
Related news
- HHS OIG to Review CMS Citationsjdsupra.com
- HHS-OIG Issues Favorable Opinion on Pharmaceutical Spoilage Replacement Programjdsupra.com
- OIG Nixes Pharmaceutical Cost-Sharing Subsidy Program Under AKSjdsupra.com
- OIG Skeptical of Medical Device and Pharmaceutical Speaker Programsjdsupra.com
- HHS OIG Posts Comprehensive Health Care Compliance Program Guidancejdsupra.com
- OIG Limits Pharmaceutical Manufacturers’ Ability to Offer Drug Cost-Sharing Subsidiesjdsupra.com
- OIG Issues Advisory Opinion Regarding Pharmaceutical Companies’ Proposed Arrangement to Provide Cost-Sharing Subsidiesjdsupra.com
- HHS OIG issues ASP reports exploring need for guidance and increased oversight in ASP reportingjdsupra.com
- HHS-OIG Guidance — Chock Full of Compliance Best Practices and Strategies (Part II of III)jdsupra.com
- HHS-OIG Enforcement Updates: Trends Relating to Telehealth Fraud Schemes and Tips to Avoid Themjdsupra.com
- OIG Permits Pharmaceutical Manufacturer to Offer Free Drug to Patients in Advisory Opinion 21-01jdsupra.com
- HHS-OIG Approves Provision of Zero-Interest Financing to Medical Device Customersjdsupra.com
- HHS OIG Creates New Taskforce to Pursue Civil Monetary Penalties and Exclusionsjdsupra.com
- Telehealth Update: A Federal Appropriations Bill, A Positive OIG Report, and Good News from HHSjdsupra.com
- HHS-OIG Warns Drug and Device Companies on Speaker Program Fraudjdsupra.com
- OIG December Enforcement Summaryjdsupra.com
- HHS OIG Updates Its Interpretation of “Nominal Value” Under CMP to $15 Per Item or $75 Per Patient Per Yearjdsupra.com
- OIG Issues Favorable Opinion Regarding Pharmaceutical Company’s Free 14-Day Drug Supply to Patients Experiencing a Delay in Coveragejdsupra.com
- OIG Issues Favorable Advisory Opinion Regarding Pharmaceutical Manufacturer Arrangement to Provide Financial Assistance to Potentially Eligible Patientsjdsupra.com
- The HHS OIG Finds Remuneration That Does Not Warrant the Imposition of the AKS or the Beneficiary Inducements CMPjdsupra.com